| Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab: First-in-human healthy volunteer trial C Voors-Pette, K Lebozec, P Dogterom, L Jullien, P Billiald, P Ferlan, ... Arteriosclerosis, thrombosis, and vascular biology 39 (5), 956-964, 2019 | 119 | 2019 |
| The future of glycoprotein VI as an antithrombotic target M Zahid, P Mangin, S Loyau, B Hechler, P Billiald, C Gachet, ... Journal of Thrombosis and Haemostasis 10 (12), 2418-2427, 2012 | 107 | 2012 |
| Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks K Lebozec, M Jandrot-Perrus, G Avenard, O Favre-Bulle, P Billiald MAbs 9 (6), 945-958, 2017 | 95 | 2017 |
| Non-invasive molecular imaging of fibrosis using a collagen-targeted peptidomimetic of the platelet collagen receptor glycoprotein VI J Muzard, L Sarda-Mantel, S Loyau, A Meulemans, L Louedec, ... PloS one 4 (5), e5585, 2009 | 86 | 2009 |
| A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector M Mousli, C Devaux, H Rochat, M Goyffon, P Billiald FEBS letters 442 (2-3), 183-188, 1999 | 66 | 1999 |
| Construction and functional evaluation of a single‐chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector C Devaux, E Moreau, M Goyffon, H Rochat, P Billiald European journal of biochemistry 268 (3), 694-702, 2001 | 65 | 2001 |
| Approach to the direct intramolecular localization of antigenic determinants in Androctonus australis hemocyanin with monoclonal antibodies by molecular immunoelectron microscopy J Lamy, J Lamy, P Billiald, PY Sizaret, G Cave, J Frank, G Motta Biochemistry 24 (20), 5532-5542, 1985 | 63 | 1985 |
| Engineering venom’s toxin-neutralizing antibody fragments and its therapeutic potential LM Alvarenga, M Zahid, A di Tommaso, MO Juste, N Aubrey, P Billiald, ... Toxins 6 (8), 2541-2567, 2014 | 62 | 2014 |
| Quaternary structure of Limulus polyphemus hemocyanin J Lamy, J Lamy, PY Sizaret, P Billiald, P Jolles, J Jolles, RJ Feldmann, ... Biochemistry 22 (24), 5573-5583, 1983 | 58 | 1983 |
| Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro J Muzard, M Bouabdelli, M Zahid, V Ollivier, JJ Lacapère, ... The FEBS Journal 276 (15), 4207-4222, 2009 | 50 | 2009 |
| Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin N Aubrey, C Devaux, PY Sizaret, H Rochat, M Goyffon, P Billiald Cellular and Molecular Life Sciences CMLS 60, 617-628, 2003 | 49 | 2003 |
| Envenomations VI. Scorpionism in Africa M Goyffon, P Billiald Medecine Tropicale: Revue du Corps de Sante Colonial 67 (5), 439-446, 2007 | 47 | 2007 |
| Grafting of protein L-binding activity onto recombinant antibody fragments J Muzard, S Adi-Bessalem, M Juste, F Laraba-Djebari, N Aubrey, ... Analytical biochemistry 388 (2), 331-338, 2009 | 44 | 2009 |
| scFv single chain antibody variable fragment as inverse agonist of the β2-adrenergic receptor JC Peter, P Eftekhari, P Billiald, G Wallukat, J Hoebeke Journal of Biological Chemistry 278 (38), 36740-36747, 2003 | 42 | 2003 |
| Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies C Fields, D O'connell, S Xiao, GU Lee, P Billiald, J Muzard Nature protocols 8 (6), 1125-1148, 2013 | 39 | 2013 |
| A method to confer Protein L binding ability to any antibody fragment Z Lakhrif, M Pugnière, C Henriquet, A Di Tommaso, I Dimier-Poisson, ... MAbs 8 (2), 379-388, 2016 | 38 | 2016 |
| Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development K Lebozec, M Jandrot-Perrus, G Avenard, O Favre-Bulle, P Billiald New biotechnology 44, 31-40, 2018 | 32 | 2018 |
| Population pharmacokinetic/pharmacodynamic modeling of glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen‐induced platelet aggregation L Renaud, K Lebozec, C Voors‐Pette, P Dogterom, P Billiald, ... The Journal of Clinical Pharmacology 60 (9), 1198-1208, 2020 | 30 | 2020 |
| Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition P Billiald, A Slater, M Welin, JC Clark, S Loyau, M Pugnière, IG Jiacomini, ... Blood Advances 7 (7), 1258-1268, 2023 | 29 | 2023 |
| Using a recombinant bispecific antibody to block Na+-channel toxins protects against experimental scorpion envenoming M Juste, MF Martin-Eauclaire, C Devaux, P Billiald, N Aubrey Cellular and molecular life sciences 64 (2), 206-218, 2007 | 29 | 2007 |
